论文部分内容阅读
１０例接受右心漂浮导管检查的慢性阻塞性肺疾病（慢阻肺）患者一次性舌下含服钾通道开放剂尼可地尔粉剂１５ｍｇ，５ｍｉｎ后肺动脉平均压由（３．１５±０．４２）ｋＰａ下降到（２．７５±０．３７）ｋＰａ，肺血管阻力由（５６．９４±８．９０）ｋＰａ·ｓ／Ｌ降至（４４．６５±６．３９）ｋＰａ·ｓ／Ｌ下降幅度分别为（１２．６９±１．８６）％和（１９．６６±３．１６）％，３０ｍｉｎ后仍维持在此水平。心输出量用药前为（３．５０±０．２８）Ｌ／ｍｉｎ，用药后为（３．９５±０．２７）Ｌ／ｍｉｎ，增加（１７．６０±４．８８）％。体动脉血压和体循环阻力无显著变化。用药后血氧饱和度和氧运输值增加，动脉血氧分压、二氧化碳分压和氢离子浓度变化不明显。结果表明尼可地尔能降低慢阻肺患者肺动脉压和肺循环阻力，且有一定选择性，可改善慢阻肺患者心功能，并增强氧运输功能。
In 10 patients with chronic obstructive pulmonary disease (COPD) undergoing right-sided floating catheterization, Nicorandil was administered as a 15 mg dose of potassium channel opener with a sublingual dose of 5 mg. The average pulmonary pressure after 5 min was (3.15 ± 0.10). 42) kPa to (2.75 ± 0.37) kPa, pulmonary vascular resistance decreased from (56.94 ± 8.90) kPa · s / L to (44.65 ± 6.39) kPa · s / L (12.69 ± 1.86)% and (19.66 ± 3.16)%, respectively, which remained at this level after 30min. Cardiac output before treatment (3.50 ± 0.28) L / min, after treatment (3.95 ± 0.27) L / min, an increase of (17.60 ± 4.88)%. No significant changes were observed in systemic arterial pressure and systemic resistance. After treatment, oxygen saturation and oxygen transport increased, arterial partial pressure of oxygen, partial pressure of carbon dioxide and hydrogen ion concentrations did not change significantly. The results show that nicorandil can reduce pulmonary hypertension in patients with COPD and pulmonary vascular resistance, and have some selectivity, can improve cardiac function in COPD patients, and enhance oxygen transport function.